The market has witnessed remarkable advancements, leveraging innovative technologies to detect and analyze CTCs in blood samples. These advancements have significantly enhanced the accuracy and efficiency of cancer diagnosis, treatment selection, and monitoring. The benefits are manifold, offering non-invasive procedures, real-time insights into tumor dynamics, and personalized treatment strategies. Furthermore, the CTC liquid biopsy market provides a promising avenue for early cancer detection, enabling timely intervention and improving patient outcomes. With ongoing research and development, this market continues to expand, offering immense potential to revolutionize cancer management and improve overall healthcare outcomes.
Data Bridge Market Research analyses that the Global Circulating Tumor Cells (CTC) Liquid Biopsy Market size was valued at USD 1,173.84 million in 2022, is expected to reach USD 4,170.06 million by 2030, growing at a CAGR of 17.17% during the forecast period of 2023 to 2030.
Below are the Top Five Circulating Tumor Cells (CTC) Liquid Biopsy Companies with a Significant Market Share:
|
Rank
|
Company
|
Overview
|
Service/Product Portfolio
|
Sales Geographical Coverage
|
Developments
|
|
1.
|
Guardant Health
|
Pioneering in liquid biopsy, Guardant Health specializes in detecting cancer through blood-based tests, including circulating tumor cells (CTCs). Their innovative technology, Guardant360, analyzes CTCs and cell-free DNA for cancer detection, monitoring, and treatment selection. Guardant's comprehensive approach enables oncologists to make informed decisions based on real-time molecular insights, improving patient care and outcomes.
|
|
North America, Middle East and Africa, Europe, South America, Asia-Pacific
|
In November 2021, Guardant Health announced the result of the study, which shows that the Guardant 360 liquid biopsy test is helping in treating patients with colorectal cancer. This will help the company to develop innovative tests.
|
|
2.
|
Eurofins Genomics
|
Although primarily known for genomic services, Eurofins Genomics has ventured into the CTC liquid biopsy market. Leveraging their expertise in genomic analysis, they offer advanced CTC isolation and characterization solutions, aiding in cancer diagnosis, prognosis, and treatment monitoring. Their integration of cutting-edge technologies with high-throughput capabilities contributes to precision medicine advancements.
|
|
North America, Middle East and Africa, Europe, South America, Asia-Pacific
|
In March 2016, Eurofins Genomics announced that it has opened a new state of the art manufacturing and services facility in Kentucky. U.S. This has helped the company to expand its geographic presence in the market.
|
|
3.
|
FOUNDATION MEDICINE, INC.
|
Renowned for its comprehensive genomic profiling (CGP) services, Foundation Medicine extends its expertise to include CTC liquid biopsy analysis. By integrating CTCs into their portfolio, Foundation Medicine provides oncologists with a holistic view of a patient's cancer landscape, facilitating personalized treatment strategies. Their precision oncology solutions, including FoundationOne Liquid CDx, empower clinicians with actionable insights derived from CTCs and other circulating biomarkers.
|
|
Europe, North America
|
In August 2021, FOUNDATION MEDICINE, INC. announced that it had partnered with Epic to integrate its genomic profiling with Epic’s electronic medical record system. This will help the company to support oncology practices in an advanced manner.
|
|
4.
|
Illumina, Inc.
|
A leader in genomic sequencing technologies, Illumina plays a significant role in advancing liquid biopsy, including CTC analysis. Illumina enables researchers and clinicians to explore CTCs' genetic signatures with high accuracy and sensitivity through their platforms and partnerships. By incorporating CTC analysis into its ecosystem, Illumina contributes to developing non-invasive cancer diagnostics and monitoring tools, driving progress in precision oncology.
|
|
Europe, Middle East and Africa, North America, South America, and Asia-Pacific
|
In August 2021, Illumin Inc. announced that it had acquired GRAIL to accelerate patient access to multi cancer early-detection tests. This will help the company to increase its product portfolio.
|
|
5.
|
Natera, Inc.
|
Natera focuses on personalized and non-invasive genetic testing solutions, including CTC-based liquid biopsies. Their innovative technology, Signatera, utilizes ultra-sensitive CTC detection methods to monitor minimal residual disease (MRD) and treatment response across various cancer types. Natera's approach offers valuable insights into disease progression and recurrence risk, empowering clinicians to tailor treatment strategies for improved patient outcomes.
|
|
North America, Middle East and Africa, South America, Europe, Asia-Pacific
|
In March 2021, Natera, Inc. announced that it has received FDA breakthrough device designation for its Signatera molecular residual disease test. This new designation will help the company to support the development of Signatera through phase III clinical trials.
|
Conclusion
In conclusion, the market exhibits promising growth fueled by technological advancements and rising cancer prevalence. The increasing demand for non-invasive diagnostic methods and personalized medicine drives market expansion. As CTC-based liquid biopsies offer real-time monitoring and treatment efficacy assessment, they present a significant opportunity for precision oncology. Harnessing these drivers will propel further innovation and adoption, revolutionizing cancer management.
